Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Target Price
The average target price of SANN.SW is 28.6 and suggests 100% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in